Research Radartracking 901 published studies · 229 human · 5 safety signals · 33 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Breast Invasive Ductal Carcinoma (IDC): Luminal A–like
Last reviewed: 9/15/2025
Applies to: ER+, PR high, HER2– with low Ki-67.
Summary
Endocrine-sensitive, lower-risk biology. Many node-negative cases avoid chemotherapy based on genomic assay support.
Pathology & Markers
ER+, PR high
HER2–
Low Ki-67
Biology & Pathways
ER signaling
CDK4/6 dependence
Clinical Challenges
Late recurrences; adherence to long endocrine therapy.
Imaging Notes
Standard breast imaging surveillance; no routine body scans when asymptomatic.